Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection

References

• Winston A, Underwood J. Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection. Curr Opin Infect Dis. 2015;28(1):17–22.10.1097/QCO.0000000000000117
   PubMed Web of Science ®Google Scholar
• Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 2015;4(3):388–395.10.5527/wjn.v4.i3.388
   PubMedGoogle Scholar
• Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22(3):395–402.10.1097/QAD.0b013e3282f423dd
   PubMed Web of Science ®Google Scholar
• Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16(9):1257–1263.10.1097/00002030-200206140-00008
   PubMed Web of Science ®Google Scholar
• Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18(7):1074–1076.10.1097/00002030-200404300-00019
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.10.1001/jama.292.2.191
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875.10.1097/QAD.0b013e328351f68f
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Ewald H, Santini-Oliveira M, et al. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015;16(5):178–189.10.1179/1945577115Y.0000000004
   PubMed Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta‐analysis: renal safety of tenofovir disoproxil fumarate in HIV‐infected patients. Clin Infect Dis. 2010;51(5):496–505.10.1086/652979
   PubMed Web of Science ®Google Scholar
• Winston J, Chonchol M, Gallant J, et al. Discontinuation of Tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies. HIV Clin Trials. 2014;15(6):231–245.10.1310/hct1506-231
   PubMed Web of Science ®Google Scholar
• Fafin C, Pugliese P, Durant J, et al. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m. Nephron – Clin Pract. 2012;120(4):c205–c214.
   PubMedGoogle Scholar
• Laprise C, Baril J-G, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56(4):567–575.10.1093/cid/cis937
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–831.10.1097/QAD.0b013e32835192ae
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89(5):513–519.10.1038/labinvest.2009.14
   PubMed Web of Science ®Google Scholar
• Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70(9):1029–1040.10.1007/s00228-014-1712-z
   PubMed Web of Science ®Google Scholar
• Gilead Sciences. Prescribing information for VIREAD^®. 2015. Available at http://www.gilead.com/~/media/files/pdfs/medicines/hiv/viread/viread_pi.pdf?la=en. Accessed November 4, 2015.
   Google Scholar
• Bristol Myers Squibb GS. Prescribing information for ATRIPLA^®. 2015. Available at http://packageinserts.bms.com/pi/pi_atripla.pdf. Accessed November 4, 2015.
   Google Scholar
• Gilead Sciences. Prescribing information for COMPLERA^®. 2015. https://gilead.com/~/media/files/pdfs/medicines/hiv/complera/complera_pi.pdf. Accessed November 4, 2015.
   Google Scholar
• Gilead Sciences. Prescribing information for STRIBILD^®. 2015. Available at http://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf?la=en. Accessed November 4, 2015.
   Google Scholar
• Hoetelmans R, Van Heeswijk R, Kestens D. Pharmacokinetic interaction between the novel nonnucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers. 3rd IAS Conference on HIV Pathogenesis, Treatment and Prevention, Brazil, July 2005, abstract WePe3.3C15.
   Google Scholar
• European Commission Health and Food Safety. Tybost product characteristics. Available at http://ec.europa.eu/health/documents/community-register/2015/20150210131020/anx_131020_en.pdf. Accessed May 2, 2016.
   Google Scholar
• Droste JA, Kearney BP, Hekster YA, Burger DM. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):37–43.10.1097/01.qai.0000191997.70034.80
   PubMed Web of Science ®Google Scholar
• Gilead Sciences. Prescribing information for emtricitabine/tenofovir disoproxil fumarate tablets (Truvada^®). Available at http://www.gilead.com/~/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf. Last updated December, 2013. Accessed November, 2015.
   Google Scholar
• Jotwani V, Scherzer R, Estrella M, et al. Associations of tenofovir disoproxil fumarate with urine biomarkers of kidney damage. Conference on Retroviruses and Opportunistic Infections (CROI): February 22–25, 2016. Boston, MA, USA2016.
   Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–455.10.1097/QAI.0b013e3182965d45
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445.10.1097/QAI.0000000000000618
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.10.1016/S0140-6736(15)60616-X
   PubMed Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–58.10.1097/QAI.0000000000000225
   PubMedGoogle Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52.10.1016/S1473-3099(15)00348-5
   PubMed Web of Science ®Google Scholar
• Rijnders B, Stephan C, Lazzarin A, et al. Switching from boosted atazanavir plus emtricitabine /tenofovir disoproxil fumarate to a tenofovir alafenamide-based single-tablet regimen: week-48 data in virologically suppressed adults [abstract 577]. 15th European AIDS Conference, October 21–24, 2015 Bacelona, Spain2015.
   Google Scholar
• Shamblaw D, Lunzen JV, Orkin C, et al. Switching from atripla (ATR) to a tenofovir alafenamide (TAF)-based single tablet regimen: week 48 data in virologically suppressed adults. ICAAC, Septemeber 17–21, 2015. San Diego, CA, USA2015.
   Google Scholar
• Thompson M, Morales-Ramirez J, McDonald C, et al. Switching from a TDF to a TAF-based single tablet regimen: week 48 data in HIV-1 infected virologically suppressed adults [abstract 725]. IDSA / ID Week, October 7–11, 2015 San Diego, CA, USA2015.
   Google Scholar
• Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. Last updated November, 2014. Available at http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v2_NOV2014.pdf. Accessed March 16, 2016.
   Google Scholar
• German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32–40.10.1097/QAI.0b013e3182645648
   PubMed Web of Science ®Google Scholar
• Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14(3):179–187.
   PubMed Web of Science ®Google Scholar
• OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 1: Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=1025. Accessed February 15, 2016.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annal Int Med. 2009;151(4):264–269, W264.10.7326/0003-4819-151-4-200908180-00135
   PubMed Web of Science ®Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.10.1136/jech.52.6.377
   PubMed Web of Science ®Google Scholar
• Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain. 1996;66(2):239–246.10.1016/0304-3959(96)03033-3
   PubMed Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412.10.1001/jama.1995.03520290060030
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–816.10.1093/cid/cir510
   PubMed Web of Science ®Google Scholar
• Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.10.1016/S0140-6736(11)60936-7
   PubMed Web of Science ®Google Scholar
• Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir Plus abacavir/lamivudine for the treatment of HIV-1 Infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515–519.10.1097/QAI.0000000000000790
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85.10.1097/QAI.0b013e31828ace69
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.10.1056/NEJMoa1215541
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.10.7326/0003-4819-154-7-201104050-00316
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448.10.1016/S0140-6736(12)60917-9
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96–100.10.1097/QAI.0b013e318289545c
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118–e120.10.1097/QAI.0000000000000057
   PubMed Web of Science ®Google Scholar
• Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16(4):199–212.
   PubMed Web of Science ®Google Scholar
• Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290.10.1371/journal.pmed.1001290
   PubMed Web of Science ®Google Scholar
• Touzard Romo F, Smeaton LM, Campbell TB, et al. Renal and Metabolic toxicities following initiation of HIV-1 Treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials. 2014;15(6):246–260.10.1310/hct1506-246
   PubMed Web of Science ®Google Scholar
• DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51(2):163–174.10.1097/QAI.0b013e3181a572cf
   PubMed Web of Science ®Google Scholar
• Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, et al. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. J Int AIDS Soc. 2013;16:18059.
   PubMed Web of Science ®Google Scholar
• Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28(7):989–997.10.1097/QAD.0000000000000169
   PubMed Web of Science ®Google Scholar
• Pujari S, Dravid A, Gupte N, Joshix K, Bele V. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. J Int AIDS Soc. 2008;10(8):196.10.1186/1758-2652-10-8-196
   PubMedGoogle Scholar
• Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74–78.10.1097/QAI.0b013e31815acab8
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18(7):905–913.10.3851/IMP2667
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713.10.1056/NEJMoa1501315
   PubMed Web of Science ®Google Scholar
• German P, Pang PS, Fang L, Chung D, Mathias A. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, November 7–11, 2014. [ Abstract.]
   Google Scholar
• Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81–91.10.1310/hct1403-81
   PubMed Web of Science ®Google Scholar
• Overton ET, Chan ES, Brown TT, et al. Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A randomized trial. Ann Intern Med. 2015;162(12):815–824.10.7326/M14-1409
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–1801.10.1093/infdis/jir188
   PubMed Web of Science ®Google Scholar
• Gupta SK, Mi D, Moe SM, Dubé MP, Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr. 2013;64(3):279–283.10.1097/QAI.0b013e3182a97c39
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Johnson M, Ribera E, Weitner L, Chen SS, Warren DR. 5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF). J Int AIDS Soc. 2010;13(Suppl 4):P6.10.1186/1758-2652-13-S4-P6
   PubMed Web of Science ®Google Scholar
• Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273–1281.10.1097/QAD.0b013e3280b07b33
   PubMed Web of Science ®Google Scholar
• Symphony Health Solutions. PatientSource APLD and Source^® PHAST prescription monthly, equivalized counts, January 2007–December 2015. http://symphonyhealth.com/product/pharmaceutical-audit-suite-phast/.
   Google Scholar
• U.S. Food and Drug Administration. Approved and Tentatively Approved Antiretrovirals in Association with the President’s Emergency Plan. http://www.fda.gov/InternationalPrograms/PEPFAR/ucm119231.htm. Accessed July 11 2016.
   Google Scholar
• World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach - Second edition (2016). http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed October 18 2016.
   Google Scholar
• Bagnis CI, Stellbrink HJ. Protease inhibitors and renal function in patients with HIV infection: a systematic review. Infect Dis Therapy. 2015;4:15–50.
   PubMed Web of Science ®Google Scholar
• Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-Infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 2012;59(1):18–24.10.1097/QAI.0b013e31823a6124
   PubMed Web of Science ®Google Scholar
• Dazo C, Fahey P, Puls R, et al. Small but significant and non-progressive decline in GFR observed in therapy-naïve HIV+ subjects commencing r/ATV, compared to either EFV or ZDV/ABC with TDF/FTC after 48 weeks: a randomized controlled study. Paper #841 presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI): February 22–March 2, 2011. Boston, MA.
   Google Scholar
• Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409–5413.10.1128/AAC.01089-12
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Titanji K, Vunnava A, et al. A single dose zoledronic acid prevents antiretroviral-induced bone loss. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, February 22–25, 2016.
   Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.10.1016/S0140-6736(09)60918-1
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55(1):39–48.10.1097/QAI.0b013e3181da1287
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191–1201.10.1093/infdis/jir505
   PubMed Web of Science ®Google Scholar
• Puls R, Amin J, Losso M, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014;383(9927):1474–1482.
   PubMed Web of Science ®Google Scholar
• Carey D, Puls R, Amin J, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15(7):793–802.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–260.10.1056/NEJMoa051871
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes – a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535–540.
   PubMed Web of Science ®Google Scholar
• Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51(5):562–568.10.1097/QAI.0b013e3181ae2eb9
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49–57.10.1097/QAI.0b013e3181dd911e
   PubMed Web of Science ®Google Scholar
• DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9(2):103–114.10.1310/hct0902-103
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Kitch D, Tierney C, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013;27(13):2069–2079.10.1097/QAD.0b013e328361d25d
   PubMed Web of Science ®Google Scholar
• Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther. 2014;19(2):191–200.10.3851/IMP2721
   PubMed Web of Science ®Google Scholar
• Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015;29(18):2459–2464.10.1097/QAD.0000000000000863
   PubMed Web of Science ®Google Scholar
• Havers FP, Detrick B, Cardoso SW, et al. Change in vitamin D levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings. PLoS ONE. 2014;9(4):e95164.10.1371/journal.pone.0095164
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir‐lamivudine versus tenofovir‐emtricitabine in HIV‐infected adults: 48‐week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–972.10.1086/652982
   PubMed Web of Science ®Google Scholar
• Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV Clin Trials. 2015;16(2):66–71.10.1179/1528433614Z.0000000010
   PubMed Web of Science ®Google Scholar